High-dose melphalan and autologous stem cell transplantation for systemic light-chain XXXX : a single institution retrospective analysis of 40 cases.

@entity1 @entity712 @entity2783 @entity3601 @entity1582 @entity299 @entity2280 @entity2259
UNASSIGNED: We report our retrospective analysis of 40 @entity1 who received high-dose melphalan and autologous stem cell transplantation for systemic immunoglobulin light-chain ( @entity1582 ) @entity2783 . Between 2006 and 2013, 40 @entity1 with @entity1582 were transplanted at our medical center. Their median age was 54  years (range 32-70  years): 18 were male. The dominant organs involved were the heart in 13 @entity1 , and kidney in 22: and other organs were involved in five. The median @entity3601 dose administered was 129 (range 50-200)  mg/m(2), and the median infused @entity2280 (+) cells was 2.69 (range 1.17-11.26)  *  10(6)/kg. Of the 40 @entity1 , 30 are alive after a median follow-up of 42 (range 12-94) months, and the 4-year estimated overall survival rate was 74  % (95  % CI 56-86  %). Four @entity1 died  <=100  days post-ASCT ( @entity712 in three @entity1 , @entity2259 in one). The 4-year estimated survival of the @entity1 with @entity299 was 54  %, significantly lower than that of the other @entity1 (91  %). Hematological and organ responses were 52 and 50  %, respectively. Careful @entity1 selection and experienced management are important, especially for @entity1 with @entity299 . It is also important to develop additional treatment for @entity1 who do not achieve a hematological and/or organ response.
